Traumatic brain injury (TBI) is a signature wound of the recent wars. How chronic TBI
symptoms develop after a mild brain injury is not fully understood, but it is now thought
that injury results in damage that reduces brain energy production, increases inflammation,
and results in a leaky blood-brain barrier. Difficulties in daily function may persist in
areas such as thinking (e.g., attention, learning, memory, planning, and problem-solving),
pain (e.g., headache) and behavior (e.g., sleep, posttraumatic stress disorder, depression).
No medications for TBI have been developed, so evidence-based cognitive rehabilitation
interventions such as Compensatory Cognitive Training (CCT) are the mainstay of treatment.
The investigators are proposing to study a medication, TTI-0102, that shows anti-inflammatory
activity, as a potential adjunct treatment with CCT for Veterans with TBI-related symptoms.
The investigators plan to first determine the best dose of TTI-0102 to use, and then to
conduct a pilot study to test the feasibility and acceptability of combining TTI-0102 with
CCT in Veterans with mild to moderate TBI and PTSD.